Curtis GB, Johnson GH, Clark P, et al.: Relative potency of controlled-release oxycodone and morphine in postoperative pain model. Eur J Clin Pharmacol. 1999; 55: 425-429.
2.
Kaiko RF, Beczkowska IW: Comparative review of daily dose requirements of Oxy-Contin® and MS Contin® in patients with non-malignant and malignant pain [poster]. Presented at the 9th World Congress on Pain. August 22-27, 1999, Vienna, Austria.
3.
Foley KM: The treatment of cancer pain. NEJM. 1985; 313: 84-95.
4.
Jacox A, Carr DB, Payne R, et al.: Management of Cancer Pain. Clinical Practice Guideline No. 9. AHCPR Pub. No. 94-0592. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, United States Department of Health and Human Services, March 1994.
5.
2000 Drug Topics® Red Book. Montvale, NJ: Medical Economics Co., Inc., 2000: 450.
6.
Glare PA, Walsh D: Dose-ranging study of oxycodone for chronic pain in advanced cancer. J Clin Oncol. 1993; 11(5): 973-978.
7.
Zhukovsky D, Walsh D, Doona M: The relative potency between high dose oral oxycodone and intravenous morphine: A case illustration. J Pain & Symptom Manage. 1999; 18(1): 53-55.
8.
Guideline for the Management of Acute and Chronic Pain in Sickle-Cell Disease. American Pain Society, August 1999.
9.
Zhukovsky D, Walsh D, Doona M: Authors’ response regarding the relative potency between high dose oral oxycodone and intravenous morphine: A case illustration. J Pain & Symptom Manage. 2000; 19(5): 326.
